Explore the groundbreaking potential of Sodium-glucose cotransporter 2 inhibitors in revolutionizing the management of lupus nephritis, a significant leap forward in nephrology care.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis?
Wagner et al., Curr Opin Rheumatol 2024
<!– DOI: 10.1097/BOR.0000000000001002 //–>
https://doi.org/10.1097/BOR.0000000000001002
Oh, the ever-evolving world of medical research, where today’s diabetes medication becomes tomorrow’s hopeful contender in the battle against lupus nephritis. Let’s dive into the magical realm of sodium-glucose cotransporter 2 (SGLT2) inhibitors, shall we? Initially hitting the scene as the cool new kids on the block for lowering blood sugar, these drugs have now been eyed for a potential side gig: slowing down the party that is chronic kidney disease and possibly reducing the guest list at the cardiovascular disease fiesta.
But wait, there’s a catch! Those big, fancy trials that showed SGLT2 inhibitors might just be the life of the chronic kidney disease party? Yeah, they didn’t invite anyone on the immunosuppression VIP list, citing concerns about party crashers like infections. So, what about our friends with lupus nephritis, you ask? Well, in the few, cozy gatherings (read: small trials) where SGLT2 inhibitors were given a chance to mingle with lupus nephritis patients, they seemed to play nice. They even helped tidy up a bit by reducing proteinuria and making modest improvements to blood pressure and BMI. But as for calming down the lupus nephritis itself? Not so much.
So, where does that leave us? It seems SGLT2 inhibitors might have a backstage pass to help manage the chronic renal and cardiovascular sideshows of lupus nephritis. But, and it’s a big but, they’re not ready for a solo performance in active disease. The advice? Let these inhibitors join the band only after the main act (kidney function) has been stabilized with the real headliners (immunosuppression) and in harmony with the backup singers (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers).
In summary, while SGLT2 inhibitors might not be the lead vocalist in the lupus nephritis concert, they could still play a crucial role in the band, provided they’re introduced at the right time. Just don’t expect them to take center stage in controlling the disease itself. Ah, the complexities of medical research—always keeping us on our toes!